Continuity Biosciences Welcomes Vicky Papoutsis to Board as Strategy Expands

Continuity Biosciences Strengthens Leadership with New Board Member

Continuity Biosciences, a clinical-stage biotechnology company, has announced the appointment of Vicky Papoutsis to its Board of Directors. This strategic decision comes as the company transitions from developing its drug delivery platform to clinical phases, recognizing the increasing importance of partnerships within the biopharmaceutical industry.

Vicky brings over 25 years of extensive experience in business development and corporate strategy, particularly in the biopharmaceutical sector. Her expertise aligns perfectly with Continuity's ongoing clinical and preclinical programs, and her track record in establishing licensing operations and business development will be crucial as the company enhances its strategic partnerships.

Currently serving as the Executive Vice President and Chief Strategy Officer at TerSera Therapeutics, Papoutsis has successfully led initiatives related to licensing agreements, mergers and acquisitions, and international operations within the biopharmaceutical landscape. Throughout her distinguished career, she has negotiated more than 30 strategic transactions and founded three successful life sciences startups backed by private equity.

The importance of her role cannot be overstated, particularly as Continuity Biosciences moves forward with its flagship program focused on pancreatic cancer, which is now in clinical phases, along with several other projects moving through its pipeline. The company aims to leverage Papoutsis’s considerable experience and insights as they navigate the complexities of clinical development and establish meaningful partnerships that drive value.

Robert Whitehead, co-founder and Executive Chairman of Continuity Biosciences, expressed his enthusiasm about Papoutsis joining the board, stating, “I have had the privilege of working with Vicky on several transactions over the years and have long respected her professionalism, strategic insight, and remarkable ability to create value through collaboration.” As the company expands its clinical and preclinical initiatives and partnership activities, Papoutsis’s experience will be invaluable.

Papoutsis herself conveyed her eagerness to contribute to the company’s direction, remarking, “It is an honor for me to join the Board of Continuity Biosciences at such a decisive moment in the company’s development.” She emphasized the exceptional leadership team and scientific advisory committee in place, along with an innovative portfolio of targeted drug delivery technologies across various therapeutic areas. By supporting the long-term strategy and expanding partnerships, she aims to play a pivotal role in achieving favorable outcomes for patients.

The addition of Papoutsis to the board enhances the collective expertise in biotechnological innovation, pharmaceutical development, corporate governance, and strategic business initiatives—an essential mix for the company’s mission.

The board members collectively bring decades of experience in founding biotechnology companies, commercializing innovative drugs, leading world-renowned health organizations, and managing billion-dollar investments, providing a robust foundation to support Continuity’s mission to transform the way medications are delivered.

Continuity Biosciences is at the forefront of developing precision drug delivery platforms designed for localized, sustained treatment modalities. Their technologies encompass intratumoral delivery for solid tumors, nanofluidic implants for prolonged release, and micropatch systems for precise intradermal administration, with a diverse project portfolio extending into oncology, type 1 diabetes, endocrinology, HIV prevention, and aesthetic medicine, bolstered by collaborations with leading universities and strategic partners.

In conclusion, the appointment of Vicky Papoutsis marks a significant step for Continuity Biosciences as it embarks on an ambitious journey to revolutionize therapeutic delivery methods and improve patient outcomes in critical health areas. With strong leadership and a focus on strategic partnerships, the company is poised for continued success in the evolving biopharmaceutical landscape.